Sometimes it might be challenging to deal with negative energy in your life
SURMOUNT-1 (Jastreboff et al., NEJM 2022) reported 22.5% body weight loss at 72 weeks at the 15 mg dose
Clinical studies indicate that both forms provide significant weight loss benefits, with some evidence suggesting oral semaglutide may even offer comparable or better outcomes in certain individuals
Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR et al
Michael Somenek, a clinical investigator in the groundbreaking Galderma study, notes that as medication-driven weight loss becomes more prolific around the world, so do the associated impacts of facial volume loss and other unwanted cosmetic effects like shadowing and hollowness. The Science Behind Facial Changes with GLP-1 Medications The 2025 Galderma clinical trial confirms what weve been observing in our practice at Aestha Clinic
We appreciate that the new procedures incorporate significant pre-service planning, intraoperative complexity, and extensive post-operative care that were not fully captured in the original codes
